Vitalli Bio Inc. terminated a potential $477 million licensing deal for autoimmune disease drug, DWP-213388, signed a year ago with Daewoong Pharmaceutical Co. Ltd., although Vitalli still retains option rights to two more dual inhibitor candidates that could fetch up to $941 million.
IL-23 receptor antagonist icotrokinra hit co-primary phase III endpoints in moderate to severe plaque psoriasis, positioning the oral peptide at the forefront of a multibillion-dollar franchise for partners Protagonist Therapeutics Inc. and Johnson and Johnson.
Endometriosis has been woefully under-recognized in the medical community, and consequently, the delay between onset and diagnosis is often quite long, with some women waiting up to 12 years for a diagnosis.
Vitalli Bio Inc. terminated a potential $477 million licensing deal for autoimmune disease drug, DWP-213388, signed a year ago with Daewoong Pharmaceutical Co. Ltd., although Vitalli still retains option rights to two more dual inhibitor candidates that could fetch up to $941 million.
Trex Bio Inc. has closed an oversubscribed $84 million series B financing round to support development of its pipeline of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
Genosco Inc. has divulged Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular and inflammatory disorders.
Eli Lilly and Co.’s chief scientific officer, Daniel Skovronsky, called peresolimab, the PD-1 agonist previously in the works by the firm for rheumatoid arthritis (RA), a “really interesting mechanism” – but not interesting enough.
Shanghai Yidi Biotechnology Co. Ltd. has patented dihydrothienopyrimidine compounds acting as phosphodiesterase PDE4B2 and/or PDE4D2 inhibitors reported to be useful for the treatment of autoimmune, metabolic diseases, neurological and inflammatory disorders.
RSS
